Journal
CLINICAL CASE REPORTS
Volume 4, Issue 12, Pages 1120-+Publisher
WILEY
DOI: 10.1002/ccr3.719
Keywords
Arrhythmia; cardiomyopathy; ibrutinib; mantle cell lymphoma; tyrosine kinase inhibitor
Categories
Ask authors/readers for more resources
Ibrutinib is a first-in-class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available